Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Artiva Biotherapeutics (ARTV) Enterprise Value (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Enterprise Value for 3 consecutive years, with -$189.3 million as the latest value for Q4 2025.

  • For Q4 2025, Enterprise Value fell 2.09% year-over-year to -$189.3 million; the TTM value through Dec 2025 reached -$189.3 million, down 2.09%, while the annual FY2025 figure was -$189.3 million, 2.09% down from the prior year.
  • Enterprise Value hit -$189.3 million in Q4 2025 for Artiva Biotherapeutics, down from -$123.0 million in the prior quarter.
  • Across five years, Enterprise Value topped out at $50.2 million in Q2 2024 and bottomed at -$189.3 million in Q4 2025.
  • Average Enterprise Value over 3 years is -$95.5 million, with a median of -$123.0 million recorded in 2025.
  • On a YoY basis, Enterprise Value climbed as much as 193.53% in 2024 and fell as far as 1036.69% in 2024.
  • Artiva Biotherapeutics' Enterprise Value stood at $19.8 million in 2023, then tumbled by 1036.69% to -$185.4 million in 2024, then dropped by 2.09% to -$189.3 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$189.3 million, -$123.0 million, and -$142.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.